CPTAC
The ability to perform larger and more complex multiomic experiments raises questions and opportunities around integrating data and extracting scientific insights.
The findings indicate similar immune activity across a broad range of cancers, suggesting common immunotherapy susceptibilities or mechanisms of resistance.
For proteomics firms, 2022 marked a reversal from an earlier boom, but the field pushed into emerging areas like single-cell, single-molecule, and spatial analyses.
Researchers inside and outside the program said it has produced new methods and a wealth of data while helping to bolster proteomics' credibility.
NCI Names Participating Centers for Latest Clinical Proteomic Tumor Analysis Consortium Stage
The institute has awarded funding to a total of 12 sites to perform proteogenomic analyses on tumor samples and to study drug response and resistance.